首頁(yè) > 抗體/蛋白 > 藥物對(duì)照抗體

瀏覽量: 114

產(chǎn)品名稱(chēng)： Research Grade Risankizumab ( 利散吉珠單抗 )
產(chǎn)品貨號(hào)： CSD00400
貨期： 現(xiàn)貨
價(jià)格與訂購(gòu)： 2480
數(shù)量：

庫(kù)存： 100
規(guī)格： 100μg

產(chǎn)品信息
如何訂購(gòu)

貨號(hào)（Catalog No.）

CSD00400

通用名INN

Risankizumab

純度(Purity)

>95%

濃度( Concentration)

1mg/ml

Formulation

PBS buffer PH7.5

Source

CHO cells

內(nèi)毒素(Endotoxin level)

Please contact with the lab for this information.

產(chǎn)品描述(Description)

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.

別名(Alternative names)

BI 655066,risankizumab-rzaa

靶點(diǎn);物種(Specificity target name;species)

IL23A[Homo sapiens]

種類(lèi)(Species)

Humanized

受體鑒定(Receptor identification)

IgG1-kappa

CAS

1612838-76-2

存儲(chǔ)條件(Storage)

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.